Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
Cytek Biosciences (CTKB) reported its Q4 and full-year 2024 financial results, showing mixed performance. Total revenue reached $200.5 million for FY2024, a 3.9% increase from 2023. The company expanded its installed base to 3,034 instruments, with 667 placements in 2024.
The company reported a net loss of $6.0 million in 2024, improved from a $12.1 million loss in 2023. Adjusted EBITDA grew significantly to $22.4 million, up 77% year-over-year. Notable developments include opening a new manufacturing facility in Singapore and completing a share repurchase of 3,971,624 shares for $21.6 million.
Looking ahead to 2025, Cytek projects revenue between $204-212 million, representing 2-6% growth. The company also announced an additional $50 million stock repurchase program for 2025.
Cytek Biosciences (CTKB) ha riportato i risultati finanziari del quarto trimestre e dell'intero anno 2024, mostrando una performance mista. Il fatturato totale ha raggiunto i 200,5 milioni di dollari per l'anno fiscale 2024, con un incremento del 3,9% rispetto al 2023. L'azienda ha ampliato la sua base installata a 3.034 strumenti, con 667 nuove installazioni nel 2024.
L'azienda ha registrato una perdita netta di 6,0 milioni di dollari nel 2024, in miglioramento rispetto a una perdita di 12,1 milioni di dollari nel 2023. EBITDA rettificato è cresciuto significativamente a 22,4 milioni di dollari, con un aumento del 77% rispetto all'anno precedente. Sviluppi notevoli includono l'apertura di un nuovo stabilimento produttivo a Singapore e il completamento di un riacquisto di azioni di 3.971.624 azioni per 21,6 milioni di dollari.
Guardando al 2025, Cytek prevede ricavi compresi tra 204 e 212 milioni di dollari, rappresentando una crescita del 2-6%. L'azienda ha anche annunciato un ulteriore programma di riacquisto di azioni da 50 milioni di dollari per il 2025.
Cytek Biosciences (CTKB) informó sus resultados financieros del cuarto trimestre y del año completo 2024, mostrando un desempeño mixto. Los ingresos totales alcanzaron los 200,5 millones de dólares para el año fiscal 2024, un aumento del 3,9% en comparación con 2023. La compañía amplió su base instalada a 3,034 instrumentos, con 667 instalaciones en 2024.
La empresa reportó una pérdida neta de 6,0 millones de dólares en 2024, mejorando respecto a una pérdida de 12,1 millones de dólares en 2023. El EBITDA ajustado creció significativamente a 22,4 millones de dólares, un aumento del 77% interanual. Los desarrollos notables incluyen la apertura de una nueva planta de fabricación en Singapur y la finalización de una recompra de acciones de 3,971,624 acciones por 21,6 millones de dólares.
De cara a 2025, Cytek proyecta ingresos entre 204 y 212 millones de dólares, lo que representa un crecimiento del 2-6%. La empresa también anunció un programa adicional de recompra de acciones de 50 millones de dólares para 2025.
Cytek Biosciences (CTKB)는 2024년 4분기 및 전체 연도 재무 결과를 발표하며 혼합된 성과를 보였습니다. 총 수익은 2024 회계연도에 2억 5백만 달러에 달하며, 2023년 대비 3.9% 증가했습니다. 이 회사는 3,034개의 장비를 설치하여 2024년에 667개의 설치를 추가했습니다.
회사는 2024년에 600만 달러의 순손실을 기록했으며, 이는 2023년의 1,210만 달러 손실에서 개선된 수치입니다. 조정된 EBITDA는 2,240만 달러로 크게 증가했으며, 전년 대비 77% 증가했습니다. 주목할 만한 발전으로는 싱가포르에 새로운 제조 시설을 개설하고 2,161만 달러에 3,971,624주를 재매입한 것입니다.
2025년을 바라보며 Cytek은 2억 4백만에서 2억 1천2백만 달러 사이의 수익을 예상하며, 이는 2-6%의 성장을 나타냅니다. 이 회사는 또한 2025년을 위한 추가 5천만 달러 규모의 주식 재매입 프로그램을 발표했습니다.
Cytek Biosciences (CTKB) a publié ses résultats financiers du quatrième trimestre et de l'année entière 2024, montrant des performances mixtes. Le chiffre d'affaires total a atteint 200,5 millions de dollars pour l'exercice 2024, soit une augmentation de 3,9 % par rapport à 2023. L'entreprise a élargi sa base installée à 3 034 instruments, avec 667 installations en 2024.
L'entreprise a enregistré une perte nette de 6,0 millions de dollars en 2024, en amélioration par rapport à une perte de 12,1 millions de dollars en 2023. EBITDA ajusté a considérablement augmenté pour atteindre 22,4 millions de dollars, soit une hausse de 77 % d'une année sur l'autre. Parmi les développements notables, on trouve l'ouverture d'une nouvelle installation de fabrication à Singapour et l'achèvement d'un rachat d'actions de 3 971 624 actions pour 21,6 millions de dollars.
Pour 2025, Cytek prévoit un chiffre d'affaires compris entre 204 et 212 millions de dollars, représentant une croissance de 2 à 6 %. L'entreprise a également annoncé un programme de rachat d'actions supplémentaire de 50 millions de dollars pour 2025.
Cytek Biosciences (CTKB) hat seine finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht, die eine gemischte Leistung zeigen. Der Gesamtumsatz belief sich im Geschäftsjahr 2024 auf 200,5 Millionen Dollar, was einem Anstieg von 3,9% im Vergleich zu 2023 entspricht. Das Unternehmen hat seine installierte Basis auf 3.034 Geräte erweitert, mit 667 Neuinstallationen im Jahr 2024.
Das Unternehmen meldete einen Nettoverlust von 6,0 Millionen Dollar im Jahr 2024, eine Verbesserung gegenüber einem Verlust von 12,1 Millionen Dollar im Jahr 2023. Bereinigtes EBITDA wuchs signifikant auf 22,4 Millionen Dollar, was einem Anstieg von 77% im Jahresvergleich entspricht. Zu den bemerkenswerten Entwicklungen gehören die Eröffnung eines neuen Produktionsstandorts in Singapur und der Abschluss eines Aktienrückkaufs von 3.971.624 Aktien für 21,6 Millionen Dollar.
Für 2025 prognostiziert Cytek einen Umsatz zwischen 204 und 212 Millionen Dollar, was einem Wachstum von 2-6% entspricht. Das Unternehmen kündigte auch ein zusätzliches Aktienrückkaufprogramm in Höhe von 50 Millionen Dollar für 2025 an.
- Adjusted EBITDA increased 77% to $22.4 million in 2024
- Net loss improved to $6.0M from $12.1M in 2023
- Revenue grew 3.9% to $200.5M in 2024
- Added 667 new instrument installations
- Announced $50M stock buyback program for 2025
- Q4 2024 revenue decreased 1.3% to $57.5M
- Gross margin declined to 55% from 57% in 2023
- Modest 2025 revenue growth guidance of 2-6%
Insights
Cytek Biosciences delivered modest revenue growth amid challenging industry conditions, with full-year 2024 revenue increasing 3.9% to
The company's profitability showed marked improvement, with full-year adjusted EBITDA surging
Cytek expanded its installed base to 3,034 instruments, adding 667 new placements in 2024. This continued market penetration of their FSP™ technology demonstrates sustained demand despite funding pressures in life sciences research markets. The new Singapore manufacturing facility represents a strategic move to improve margins through lower production costs while enhancing supply chain resilience.
The company's
Looking ahead, Cytek's 2025 revenue guidance of
FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024.
Recent Highlights
- Total revenue was
$200.5 million , or$201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing3.9% and3.9% increases, respectively, over the full year 2023 - Expanded total Cytek installed base to 3,034 instruments, with 667 total instruments placed during the full year 2024
- Net loss in the year ended December 31, 2024 was
$6.0 million compared to net loss of$12.1 million in the year ended December 31, 2023 - Total adjusted EBITDA was
$22.4 million for the full year of 2024, a gain of77% over the full year 2023. Adjusted EBITDA excluding investment income was$14.4 million for the full year 2024 compared to$5.2 million for the full year 2023, a gain of128% - Opened a new manufacturing facility in Singapore to access low-cost manufacturing, increase capacity and enhance global supply flexibility
- Repurchased a total of 3,971,624 shares of common stock at an aggregate cost of approximately
$21.6 million from June through year end 2024Announced a stock repurchase program for up to an additional aggregate of$50 million in 2025
“I am pleased with our continued market penetration with our FSP™ technology, the increased number of instrument deployments and a substantial increase in adjusted EBITDA and positive cash flow generation in what continues to be a dynamic industry environment. Our full-year results reflect our team’s strong focus on execution of our growth strategy and the leadership, strength, and resilience of the Cytek platform,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences. “Looking ahead, as we continue our path to further advance Cytek as a market leader in cell analysis, the durable foundation we have built provides us with confidence in our expectations and our long-term objective of delivering sustainable growth and profitability.”
Fourth Quarter 2024 Financial Results
Total revenue for the fourth quarter of 2024 was
Gross profit was
Operating expenses were
Research and development expenses were
Sales and marketing expenses were
General and administrative expenses were
Income from operations in the fourth quarter of 2024 was
Net income in the fourth quarter of 2024 was
Adjusted EBITDA in the fourth quarter of 2024 was
Full Year 2024 Financial Results
Total revenue for the year ended December 31, 2024 was
Gross profit was
Operating expenses were
Research and development expenses were
Sales and marketing expenses were
General and administrative expenses were
Loss from operations in the year ended December 31, 2024 was
Total adjusted EBITDA in the year ended December 31, 2024 was
Cash, cash equivalents, restricted cash and short-term investments in marketable securities were
2025 Outlook
Cytek Biosciences expects total revenue for the year ended December 31, 2025 to be in the range of
Webcast Information
Cytek will host a conference call to discuss its fourth quarter and year end 2024 financial results on Thursday, February 27, 2024, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.
About Cytek Biosciences
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™ and Northern Lights™ systems and the Cytek Aurora CS cell sorter; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Enhanced Small Particle, ESP, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Statement Regarding Use of Non-GAAP Financial Information
Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and also on a non-GAAP basis for the three-month period and full year period ended December 31, 2024 and December 31, 2023. Management believes that non-GAAP financial measures, including “Adjusted gross margin,” “Adjusted gross profit,” “Adjusted EBITDA,” “Adjusted EBITDA excluding investment income,” revenue on a “constant currency basis,” operating expenses (excluding the non-recurring benefit from an adjustment to a license and royalty settlement liability), general and administrative expenses (excluding the non-recurring benefit from an adjustment to a license and royalty settlement liability), income from operations (excluding the non-recurring benefit from an adjustment to a license and royalty settlement liability) and net income/loss from operations (excluding the after-tax contribution to net income from the non-recurring benefit from an adjustment to a license and royalty settlement liability) referenced above, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Forward-Looking Statements
This press release and the related conference call, webcast and presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, without limitation, statements regarding Cytek’s growth strategy; Cytek’s market opportunities and positioning to serve a large and growing cell analysis market; the potential to deliver sustainable growth and profitability; Cytek’s future financial performance, including its outlook for fiscal year 2025 and expectations for 2025 total revenue; Cytek’s expectations of increased capacity and enhanced global supply flexibility following the opening of its Singapore manufacturing facility; and the impacts of new export controls and licensing requirements on Cytek’s business and industry. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled “Risk Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024, Cytek’s Annual Report on Form 10-K to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release and the related conference call, webcast and presentation are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Relations Contact:
Paul D. Goodson
Head of Investor Relations
pgoodson@cytekbio.com
| Cytek Biosciences, Inc. Consolidated Balance Sheets (Unaudited) | ||||||||
| (In thousands, except share and per share data) | December 31, 2024 | December 31, 2023 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 98,716 | $ | 167,299 | ||||
| Restricted cash | 29 | 331 | ||||||
| Marketable securities | 179,145 | 95,111 | ||||||
| Trade accounts receivable, net | 60,588 | 55,928 | ||||||
| Inventories | 43,893 | 60,877 | ||||||
| Prepaid expenses and other current assets | 14,075 | 12,514 | ||||||
| Total current assets | 396,446 | 392,060 | ||||||
| Deferred income tax assets, noncurrent | 33,374 | 30,487 | ||||||
| Property and equipment, net | 17,962 | 18,405 | ||||||
| Operating lease right-of-use assets | 10,168 | 10,853 | ||||||
| Goodwill | 16,663 | 16,183 | ||||||
| Intangible assets, net | 20,128 | 23,084 | ||||||
| Other noncurrent assets | 4,759 | 3,385 | ||||||
| Total assets | $ | 499,500 | $ | 494,457 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Trade accounts payable | $ | 5,529 | $ | 3,032 | ||||
| Legal settlement liability, current | 1,705 | 2,561 | ||||||
| Accrued expenses | 21,443 | 20,035 | ||||||
| Other current liabilities | 13,494 | 7,903 | ||||||
| Deferred revenue, current | 25,492 | 22,695 | ||||||
| Total current liabilities | 67,663 | 56,226 | ||||||
| Legal settlement liability, noncurrent | 9,036 | 16,477 | ||||||
| Deferred revenue, noncurrent | 16,098 | 15,132 | ||||||
| Operating lease liability, noncurrent | 7,552 | 9,479 | ||||||
| Long term debt | 1,050 | 1,648 | ||||||
| Other noncurrent liabilities | 2,364 | 2,431 | ||||||
| Total liabilities | $ | 103,763 | $ | 101,393 | ||||
| Stockholders’ equity: | ||||||||
| Common stock, | 129 | 131 | ||||||
| Additional paid-in capital | 430,791 | 423,386 | ||||||
| Accumulated deficit | (35,199 | ) | (29,178 | ) | ||||
| Accumulated other comprehensive gain (loss) | 16 | (1,275 | ) | |||||
| Total stockholders’ equity | 395,737 | 393,064 | ||||||
| Total liabilities and stockholders’ equity | $ | 499,500 | $ | 494,457 | ||||
| Cytek Biosciences, Inc. Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) | ||||||||||||
| (In thousands, except share and per share data) | 2024 | 2023 | 2022 | |||||||||
| Revenue, net: | ||||||||||||
| Product | $ | 153,263 | $ | 156,717 | $ | 148,600 | ||||||
| Service | 47,190 | 36,298 | 15,436 | |||||||||
| Total revenue, net | 200,453 | 193,015 | 164,036 | |||||||||
| Cost of sales: | ||||||||||||
| Product | 69,088 | 65,327 | 49,955 | |||||||||
| Service | 20,259 | 18,262 | 13,107 | |||||||||
| Total cost of sales | 89,347 | 83,589 | 63,062 | |||||||||
| Gross profit | 111,106 | 109,426 | 100,974 | |||||||||
| Operating expenses: | ||||||||||||
| Research and development | 39,402 | 44,151 | 34,858 | |||||||||
| Sales and marketing | 49,114 | 49,148 | 33,230 | |||||||||
| General and administrative | 43,113 | 43,972 | 34,690 | |||||||||
| Total operating expenses | 131,629 | 137,271 | 102,778 | |||||||||
| Loss from operations | (20,523 | ) | (27,845 | ) | (1,804 | ) | ||||||
| Other income (expense): | ||||||||||||
| Interest income (expense), net | 5,239 | (2,071 | ) | (2,573 | ) | |||||||
| Interest income | 5,121 | 6,413 | 4,619 | |||||||||
| Other income, net | 4,463 | 7,794 | 1,018 | |||||||||
| Total other income, net | 14,823 | 12,136 | 3,064 | |||||||||
| (Loss) income before income taxes | (5,700 | ) | (15,709 | ) | 1,260 | |||||||
| Provision for (benefit from) income taxes | 320 | (3,561 | ) | (1,224 | ) | |||||||
| Net (loss) income | $ | (6,020 | ) | $ | (12,148 | ) | $ | 2,484 | ||||
| Less: net loss allocated to noncontrolling interests | — | — | 92 | |||||||||
| Net (loss) income attributable to common stockholders, basic and diluted | $ | (6,020 | ) | $ | (12,148 | ) | $ | 2,576 | ||||
| Net (loss) income attributable to common stockholders per share, basic | $ | (0.05 | ) | $ | (0.09 | ) | $ | 0.02 | ||||
| Net (loss) income attributable to common stockholders per share, diluted | $ | (0.05 | ) | $ | (0.09 | ) | $ | 0.02 | ||||
| Weighted-average shares used in calculating net (loss) income per share, basic | 130,611,330 | 135,283,044 | 134,510,831 | |||||||||
| Weighted-average shares used in calculating net (loss) income per share, diluted | 130,611,330 | 135,283,044 | 138,562,111 | |||||||||
| Comprehensive (loss) income: | ||||||||||||
| Net (loss) income | $ | (6,020 | ) | $ | (12,148 | ) | $ | 2,484 | ||||
| Foreign currency translation adjustment, net of tax | 1,193 | (549 | ) | (1,611 | ) | |||||||
| Unrealized gain (loss) on marketable securities | 97 | (29 | ) | 17 | ||||||||
| Net comprehensive (loss) income | $ | (4,730 | ) | $ | (12,726 | ) | $ | 890 | ||||
| Reconciliation of GAAP to Non-GAAP Measures (Unaudited) | ||||||||
| Three months ended | ||||||||
| (In thousands) | December 31, 2024 | December 31, 2023 | ||||||
| GAAP Gross profit | $ | 33,652 | $ | 33,048 | ||||
| Stock based compensation | 1,139 | 824 | ||||||
| Amortization of acquisition-related intangible assets | 498 | 610 | ||||||
| Non-GAAP Adjusted gross profit | $ | 35,289 | $ | 34,482 | ||||
| GAAP Gross margin | 59 | % | 57 | % | ||||
| Non-GAAP Adjusted gross margin | 61 | % | 59 | % | ||||
| GAAP Net income | $ | 9,643 | $ | 5,503 | ||||
| Depreciation and amortization | 2,849 | 2,423 | ||||||
| Provision for (benefit from) income taxes | 680 | (1,392 | ) | |||||
| Interest income | (913 | ) | (1,447 | ) | ||||
| Interest (income) expense, net | (5,933 | ) | 393 | |||||
| Foreign currency exchange loss (gain) | 1,764 | (1,255 | ) | |||||
| License and royalty settlement adjustment | (2,561 | ) | — | |||||
| Stock based compensation | 7,003 | 5,669 | ||||||
| Acquisition related expenses | — | — | ||||||
| Non-GAAP Adjusted EBITDA | $ | 12,532 | $ | 9,894 | ||||
| Investment income | (2,298 | ) | (1,897 | ) | ||||
| Non-GAAP Adjusted EBITDA excluding investment income | $ | 10,234 | $ | 7,997 | ||||
| Reconciliation of GAAP to Non-GAAP Measures (Unaudited) | ||||||||
| Twelve months ended | ||||||||
| (In thousands) | December 31, 2024 | December 31, 2023 | ||||||
| GAAP Gross profit | $ | 111,106 | $ | 109,426 | ||||
| Stock based compensation | 4,438 | 3,213 | ||||||
| Amortization of acquisition-related intangible assets | 1,997 | 1,721 | ||||||
| Non-GAAP Adjusted gross profit | $ | 117,541 | $ | 114,360 | ||||
| GAAP Gross margin | 55 | % | 57 | % | ||||
| Non-GAAP Adjusted gross margin | 59 | % | 59 | % | ||||
| GAAP Net loss | $ | (6,020 | ) | $ | (12,148 | ) | ||
| Depreciation and amortization | 10,595 | 9,230 | ||||||
| Provision for (benefit from) income taxes | 320 | (3,561 | ) | |||||
| Interest income | (5,121 | ) | (6,413 | ) | ||||
| Interest (income) expense, net | (5,240 | ) | 2,071 | |||||
| Foreign currency exchange loss (gain) | 3,597 | (108 | ) | |||||
| License and royalty settlement adjustment | (2,561 | ) | — | |||||
| Stock based compensation | 26,848 | 22,048 | ||||||
| Acquisition related expenses | — | 1,512 | ||||||
| Non-GAAP Adjusted EBITDA | $ | 22,418 | $ | 12,631 | ||||
| Investment income | (8,016 | ) | (7,420 | ) | ||||
| Non-GAAP Adjusted EBITDA excluding investment income | $ | 14,402 | $ | 5,211 | ||||
| Revenue | Three months ended December 31, 2024 (Unaudited) | Three months ended December 31, 2023 (Unaudited) | |||
| As reported | 57,476 | 58,234 | |||
| Non-GAAP constant currency | 58,590 | 57,795 | |||
| FX Impact [$] | 1,114 | (439 | ) | ||
| FX Impact [%] | 1.9 | % | (0.8 | )% | |
| Revenue | Twelve months ended December 31, 2024 (Unaudited) | Twelve months ended December 31, 2023 (Unaudited) | |||
| As reported | 200,453 | 193,015 | |||
| Non-GAAP constant currency | 201,346 | 193,697 | |||
| FX Impact [$] | 893 | 682 | |||
| FX Impact [%] | 0.4 | % | 0.4 | % | |
FAQ
What is Cytek Biosciences (CTKB) revenue guidance for 2025?
How many instruments did Cytek Biosciences (CTKB) install in 2024?
What was CTKB's share repurchase activity in 2024?
How much did Cytek's (CTKB) Adjusted EBITDA improve in 2024?
What strategic expansion did CTKB announce in 2024?
